TBGNF Stock UPDATES Thromboogenics Nv (TBGNF) 12.1000 08/11/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Thromboogenics Nv (TBGNF) 12.1000 $TBGNF

ThromboGenics Plays Long Game for Eye Disease
Catherine Shaffer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
ThromboGenics NV recently announced that it received a 3 million euro grant from the Flemish agency for Innovation by Science and Technology to support development of new therapeutics for diabetic macular edema. The new program will complement...

ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema
PR Newswire Europe - Thu Sep 05, 12:31AM CDT
LEUVEN, Belgium, September 5, 2013 /PRNewswire/ --

Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Acute Ischemic Stroke - Pipeline Review, H2 2013 Report Assists you in Identifying Players of the Most Promising Pipeline
M2 - Mon Sep 02, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/jcs2gq/acute_ischemic) has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acute Ischemic Stroke - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke. Acute Ischemic Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Acute Ischemic Stroke. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Ischemic Stroke pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - D-Pharm Ltd. - Daiichi Sankyo Company, Ltd - FCB-Pharmicell Co.,Ltd. - Gaia BioPharma Limited - Glucox Biotech - H Lundbeck A/S - M's Science Corporation - Manipal AcuNova Ltd - Mitsubishi Tanabe Pharma Corporation - Oxygen Biotherapeutics, Inc. - PhytoHealth Corporation - Reliance Life Sciences Pvt. Ltd. - Remedy Pharmaceuticals, Inc. - Sanofi-Aventis - Stem Cell Therapeutics Corp. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/jc...e_ischemic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Health Canada Approves ThromboGenics' JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion
PR Newswire - Fri Aug 16, 9:13AM CDT
Canada is first market outside the US and Europe where JETREA® is approved

Germany's IQWiG Confirms That ThromboGenics' JETREA(R) Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole
PR Newswire Europe - Fri Aug 02, 12:31AM CDT
LEUVEN, Belgium, August 2, 2013 /PRNewswire/ --

Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole
PR Newswire - Fri Aug 02, 12:30AM CDT
ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the German Institute for Quality and Efficiency in Health Care (IQWiG) has confirmed that JETREA® (ocriplasmin) demonstrates major / significant added value in VMT patients with mild / moderately severe symptoms compared with existing comparative treatment, when treating vitreomacular traction (VMT) including when associated with a macular hole of less than or equal to 400 microns.

ThromboGenics' JETREA(R) Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole
PR Newswire Europe - Wed Jun 12, 12:01AM CDT
LEUVEN, Belgium, June 12, 2013 /PRNewswire/ --

ThromboGenics' JETREA® Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole
PR Newswire - Wed Jun 12, 12:00AM CDT
ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces today that the UK's National Institute for Health and Care Excellence (NICE) has provisionally recommended JETREA® (ocriplasmin) for reimbursement within the National Health Service (NHS). The NICE Appraisal Consultation Document (ACD) initially recommends JETREA® as an option for treating vitreomacular traction (VMT) in adults, including when associated with a macular hole of less than or equal to 400 microns, when patients have severe symptoms and an epiretinal membrane is not present.

ThromboGenics Licenses Innovative Technology from Eleven Biotherapeutics to Develop Novel Drugs for the Treatment of Diabetic Eye Diseases
PR Newswire Europe - Tue May 28, 11:03AM CDT
LEUVEN, Belgium, May 28, 2013 /PRNewswire/ --

Eleven Biotherapeutics Announces Collaboration with ThromboGenics to Develop a Novel Protein Therapeutic for Ophthalmic Disease
Business Wire - Tue May 28, 10:45AM CDT
Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics for the treatment of ocular diseases, announced today that they have entered into a research collaboration and license agreement with ThromboGenics NV to research and develop a protein therapeutic based on a novel biologic target implicated in ophthalmic disease. The collaboration aims to employ Eleven's proprietary AMP-Rx protein design technology to optimize a novel therapeutic of ThromboGenics' selection to have improved pharmaceutical characteristics and therapeutic benefits. The novel biologic will be designed to treat back of the eye diseases such as diabetic macular edema.

ThromboGenics' JETREA® Launched in Denmark and Sweden
PR Newswire - Mon May 27, 10:45AM CDT
Roll out in Finland and Norway to follow shortly

ThromboGenics Business Update
PR Newswire Europe - Thu May 16, 11:16AM CDT
LEUVEN, Belgium, May 16, 2013 /PRNewswire/ --

ThromboGenics' JETREA(R) Available in Germany Public and Private Market
PR Newswire Europe - Thu May 02, 12:31AM CDT
LEUVEN, Belgium, May 2, 2013 /PRNewswire/ --

ThromboGenics' JETREA® Available in Germany Public and Private Market
PR Newswire - Thu May 02, 12:30AM CDT
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA® in Germany, the second European market where the product is now available.

Thrombocytopenia - Pipeline Review, H1 2013
M2 - Wed Apr 24, 5:49AM CDT
Research and Markets has announced the addition of the Thrombocytopenia - Pipeline Review, H1 2013 report to their offering. 'Thrombocytopenia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thrombocytopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thrombocytopenia. Scope - A snapshot of the global therapeutic scenario for Thrombocytopenia. - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thrombocytopenia pipeline on the basis

ThromboGenics' JETREA®, the First and Only Medicine for Treating Vitreomacular Traction, now Launched in the UK
PR Newswire - Thu Apr 11, 10:45AM CDT
First EU JETREA® order triggers EUR45 million milestone payment from Alcon to ThromboGenics

ThromboGenics Starts Trading as Part of the BEL20 Index Today
PR Newswire Europe - Mon Mar 18, 1:31AM CDT
LEUVEN, Belgium, March 18, 2013 /PRNewswire/ --




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mall of America Strives for World Record This Black Friday

Updated Category News Views 67

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 49

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 182

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 108

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 63

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 32

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Parallels Desktop Tops 2026 Picks for Windows on Mac

Updated Category News Views 41

Diving into the Cross-Platform Conundrum Now, I've been in the trenches long enough to know that when companies start relying on Mac computers but can't ditch their essential Windows apps, they're bound to hit a digital brick wall. Picture this—accounting, enterprise management, all that jazz that still needs Windows to function. For those jumping between these two...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 77

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 111

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading

Top 5 Most Recently Viewed Articles

Geleximco Group Partners with Leekr Technology for Innovation

Updated Category News Views 271

Introduction to a New Era of Collaboration Geleximco Group has recently established an exciting partnership with Leekr Technology, a prominent player in the intelligent chassis systems sector. This collaboration aims to significantly enhance the automotive manufacturing capabilities in the region. By leveraging their combined expertise, both companies are poised to make...

Continue Reading
Enerpac Tool Group's Earnings Preview and Stock Insights

Updated Category News Views 72

Enerpac Tool Group's Upcoming Earnings Announcement Enerpac Tool Group (NYSE: EPAC) is set to release its quarterly earnings report shortly. This announcement is pivotal for both current investors and those considering an investment in the company. With analysts predicting an earnings per share (EPS) of $0.53, excitement is building around whether Enerpac will meet or...

Continue Reading
Analyzing Rocket Lab's Options Activity for Investors

Updated Category News Views 185

Understanding Rocket Lab's Options Activity In recent trading, substantial bearish sentiment has emerged among investors of Rocket Lab (NASDAQ: RKLB), which should capture the attention of market observers. Tracking public options records reveals a significant uptick in activity, indicating that something potentially impactful could be on the horizon for the company....

Continue Reading
Greenway Health Collaborates with AWS to Innovate Healthcare

Updated Category News Views 284

Greenway Health Joins Forces with AWS Partner Network The collaboration enhances Greenway's ambulatory solutions and paves the way for full cloud migration. Advancing Healthcare Technology Greenway Health is excited to announce its membership in the Amazon Web Services (AWS) Partner Network (APN), marking a significant step in improving healthcare access and efficiency....

Continue Reading
Intel's Future Prospects: An Acquisition Target or Growth Story?

Updated Category News Views 335

Intel Corp: A New Chapter Amid Market Challenges Intel Corp (NASDAQ: INTC) experienced a notable uptick in stock value recently, spurred by reports suggesting that it may become an acquisition target. This news arrives as the semiconductor giant grapples with a significant decline in its stock price, which has dropped by approximately 54% over the past year. Speculative...

Continue Reading